Trinity Biotech (TRIB)

[cheapbastard]

Here's some insight into TRIB $$$

THE CURRENT BREAD N BUTTER:
Principal Products:



The brand names of the principal products of Trinity Biotech are listed below, organised first by point of use and second by application. The trademarks and registered marks noted below are owned by Trinity Biotech.
Trinity Biotech also sells raw materials to the life sciences industry and research institutes globally through its wholly owned subsidiary, Benen Trading Ltd., trading as Fitzgerald Industries. Trinity Biotech sells its products through its direct sales organisations in the United States, Brazil and to an extent the United Kingdom, and through its network of principal distributors and non-governmental bodies into approximately 100 countries globally.

Point-Of-Care Clinical Laboratory Infectious Diseases Emergency Medicine Infectious Diseases Haemoglobin Autoimmune Clinical Chemistry Blood Bank Screening UniGold™ Meritas Bartels Premier™ ImmuBlot™ EZ™ Captia™ Recombigen MarDx Ultra ImmuGlo™ MicroTrak™ MarBlot ImmuLisa™ OTOblot™

Trinity has also developed a BNP test on the same platform. BNP is a biomarker utilised in aiding the diagnosis of and determining the clinical severity of acute and chronic heart failure. In addition, BNP can be useful in a wide range of clinical applications including risk stratification and monitoring of patients with heart failure and heart attacks. CE marking and EU regulatory approval was received for this product in September 2014. US clinical studies for the product commenced in 2015, and submission to the FDA is anticipated in mid-2016. Once approved, the BNP assay will run side by side, on the same platform as Trinity’s Troponin product. Once the combined product offering is approved for commercialisation, Trinity will be positioned to successfully target and compete in the combined BNP and Troponin point-of-care market. The cardiac point-of-care market is estimated to be US$1 billion per year.

A top priority for Trinity Biotech is to expand its offering on the Meritas POC Analyser. The focus of our development efforts is to continue to expand the test menu to include assays for deep vein thrombosis and pulmonary embolism (D-dimer), and other highly valuable areas of need in emergency medicine. Currently, Trinity Biotech offers the Meritas Troponin and BNP products for sale in Europe and other selected markets through its specialist Cardiology Distributor network. Trinity Biotech will launch the products in the U.S. following FDA clearance.


it sells, just not in the U.S. .... YET!

http://www.trinitybiotech.com/wp-content/uploads/2015/01/Form-20-F-2015.pdf

page 29.
page 30.

SIDEWAYS TRADING IS WAY BETTER THAN THE SLOW BLEED. I'll wait for the pop.